Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.75 |
| ▸ | CDC25B | P30305 | 2/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758972 | 1.00 | HPGD (0.75) | HPGDCDC25BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6865960 | 0.86 | HPGD (1.00) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL1299907 | 0.86 | HPGD (1.00) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL1299906 | 0.86 | HPGD (1.00) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL497030 | 0.84 | DYRK1A (0.67) | HPGDCDC25BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL497031 | 0.84 | DYRK1A (0.67) | HPGDCDC25BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5756348 | 0.82 | PPARG (0.64) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5758206 | 0.82 | HPGD (0.72) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5756346 | 0.82 | PPARG (0.64) | HPGDPTPN1POLBMAOAMAOB | |
| SCHEMBL5758203 | 0.82 | HPGD (0.72) | HPGDPTPN1POLBMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | claimed |
| EP-1179343-B1 | REMEDIES FOR DIABETES COMPRISING 2-(N-CYANOIMINO)THIAZOLIDINE-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2004-08-18 | — | — | EP | claimed |
| CN-1159305-C | Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives | ��ʽ���縻��Ħ���������� | 2004-07-28 | — | — | CN | claimed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | claimed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | claimed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | claimed |
| CN-1333762-A | Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives | FUJIMOTO BROTHERS CO LTD (JP) | 2002-01-30 | — | — | CN | claimed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-1142885-B1 | 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | FUJIMOTO BROTHERS CO LTD (JP) | 2006-11-15 | — | — | EP | disclosed |
| CN-1159305-C | Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives | ��ʽ���縻��Ħ���������� | 2004-07-28 | — | — | CN | disclosed |
| US-6667328-B2 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO BROTHERS CO., LTD. (JP) | 2003-12-23 | — | — | US | disclosed |
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | FUJIMOTO CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6380229-B1 | USEFUL FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDEMIA AND RELATED COMPLICATIONS | FUJIMOTO CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-1179343-A1 | REMEDIES FOR DIABETES | Fujimoto Brothers Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| CN-1333762-A | Novel 2-(N-cyanoimino) thiazolidin-4-one derivatives | FUJIMOTO BROTHERS CO LTD (JP) | 2002-01-30 | — | — | CN | disclosed |
| EP-1142885-A1 | NOVEL 2-(N-CYANOIMINO)THIAZOLIDIN-4-ONE DERIVATIVES | Fujimoto Brothers Co., Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078193-A1 | Such as 2-(N-Cyanoimino)-5-((E)-4-styrylbenzylidene)thiazol-idin-4-one; prophylaxis of hypolipidemic/hypoglycemic, hyper-/hypo-cholesterolemia activity | APOL1, NR1H2, CYP8B1 | HPGD 3242/4885CDC25B 3989/4885CSNK2A2 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.